BioSpace News Archive

The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.

Distribution partnership with one of Cyprus’s most established healthcare and consumer-products distributor Highlights: • LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement. • Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. • Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement. • CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or non-evaluable samples; previously reported EuroFlow comparison data are also summarized.